Provista Diagnostics, Inc. has developed the first protein-based blood test, Videssa® Breast for early and accurate detection of breast cancer in women ages 25-75. 

Updating procedures

This simple blood test was created as an ideal diagnostic complement to imaging, providing real-time results for greater confidence and clarity in clinical decision making. Combining protein signatures with conventional imaging provides a more comprehensive evaluation, allowing for earlier, more accurate breast cancer detection.

"...80 percent of the 1.6 million biopsies performed each year on women with questionable imaging findings are diagnosed as benign (false positive)."

While mammography is the current gold standard for breast cancer screening, its limitations are well-known. This is why various imaging technologies are currently used. Current methods of detection do not meet the needs of all patient populations, such as patients with dense breasts or questionable mammographic findings.

Accuracy saves

Thirty to forty percent of breast cancer goes undetected by mammography in women with dense breasts and approximately 80 percent of the 1.6 million biopsies performed each year on women with questionable imaging findings are diagnosed as benign (false positive). A protein-based blood test provides a complementary diagnostic approach that will reduce false positive and false negative results to improve accuracy of detection when clinical assessment is challenging.

Videssa Breast is a Laboratory Developed Test, currently approved for sale in 49 states. Provista anticipates launching Videssa Breast in 2016, upon publication of clinical trial results in well-established, peer-reviewed journals. At that time, Videssa Breast will have data from two prospective, randomized clinical trials with over 1,350 women ages 25-75 from 15 breast cancer centers across the US. For more information on Videssa Breast or Provista Diagnostics, please visit ProvistaDx.com.